Carolinas HealthCare System

Research and Clinical Trials

Multiple Myeloma 

Brief Description PrincipalĀ Investigator
This multicenter Phase 2 study is designed to assess the efficacy and safety of ARRY-520 in approximately 160 patients with multiple myeloma who have received at least 2 prior lines of therapy; have received prior bortezomib and lenalidomide; and have disease refractory to carfilzomib and/or pomalidomide Usmani, Saad 
Estimate the progression-free survival (PFS) of patients treated with carfilzomib + ARRY-520 and of patients treated with single-agent carfilomib. Usmani, Saad 
To compare the efficacy of daratumumab when combined with
lenalidomide and dexamethasone (DRd) to that of lenalidomide and
dexamethasone (Rd), in terms of progression-free survival (PFS) in
subjects with relapsed or refractory multiple myeloma.
Usmani, Saad 
To collect high quality specimens from patients with hematologic disorders and normal volunteers.
Future specimen analyses will be performed to determine the differences between sick and normal cells. Data used for these comparisons will include, but are not limited to: gene expression data, DNA, RNA, epigenetics, proteomics, metabolomics, and pathway analysys.
Avalos, Belinda Rene 
Phase 1b: To determine the maximum tolerated dose and identify the recommended Phase 3 dose of oprozomib in combination with pomalidomide and dexamethasone.
Phase 3: To compare progression-free survival between subjects treated with OPomD versus those treated with PomD.
Usmani, Saad 
About Carolinas HealthCare System
Who We Are
Community Benefit
Corporate Financial Information
Diversity & Inclusion
Annual Report
Patient Links
Pay Your Bill
Hospital Pre-Registration
Patient Rights
Financial Assistance
Quality & Value Reports
Join Carolinas HealthCare System
Physician Careers

For Employees
Carolinas Connect
Connect with Us
Watch Carolinas HealthCare on YoutubeFollow Carolinas HealthCare on TwitterLike Carolinas HealthCare on FacebookContact Carolinas HealthCareJoin Carolinas HealthCare on LinkedInGo to our mobile website.